Ariceum Therapeutics GmbH

BERLIN, April 4, 2024 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it will be presenting a poster, demonstrating its new findings on the discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display in collaboration with research partner, UCB, a global pharmaceutical company, at this year's American Association for Cancer Research (AACR) Annual Meeting, held 5-10 April 2024 in San Diego, California. The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™. Macrocyclic peptides are potent ligands for radioligand therapeutics (RLT) that aim to selectively deliver radioisotopes to cancer tissues to eradicate tumor cells while limiting the damage to surrounding tissues. This new data highlights the potential of UCB's mRNA display platform for fast and efficient discovery of highly specific macrocyclic peptides with optimal binding properties suitable for RLT. Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: "Following our exclusive, strategic research collaboration with UCB, we look forward to presenting new findings related to the identification of highly specific macrocyclic peptides for use in radioligand therapeutics at this year's AACR Annual Meeting. These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy. AACR's Annual Meeting is the perfect industry forum at the forefront of cancer research at which to present our findings." Details of the poster presentation are as follow: Title: Discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display Presenting Author: Anika Jaekel, Senior Director, Head of Translational Biology and Non-Clinical Pharmacology at Ariceum Therapeutics Session Category: Experimental and Molecular Therapeutics Session Title: Radiation, Theranostics, Radiotheranostics, Normal Tissue, and Cellular Stress Session Date and Time: Tuesday 9 April 2024, 1:30 PM - 5:00 PM PDT Location: Poster Section 29 Poster Board Number: 7 Abstract Number: 6025 Abstracts are available in an online itinerary planner here and will be available in on online only supplement to the AACR journal Cancer Research one month after the conference. Notes to Editors About Ariceum Therapeutics Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of 'Marie Curie' whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum's lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan ("Satoreotide"), is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), or Merkel Cell Carcinoma, all of which have few treatment options and poor prognosis. Satoreotide is being developed as a 'theranostic' pair for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), which is slated to enter clinical development in 2024. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023. Ariceum Therapeutics, launched in 2021, acquired all rights to Satoreotide from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, United Kingdom and United States of America and with activities currently across the globe. Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For further information, please visit . About AACR Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 54,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 130 countries and territories around the world. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting. For more information about the AACR, visit AACR.org. SOURCE Ariceum Therapeutics

Radiopharmaceuticals are poised for a boom in the next decade! Analysts predict a surge in the market, driven by a perfect storm of factors. Public and private healthcare companies are pouring more money into this field, and cancer rates are rising globally. This report by FMI dives deep into why this market is thriving, what bumps it might face, and the exciting possibilities ahead. NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide. With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade. Rising incidences of cancer and cancer-associated diseases are one of the main reasons for that. Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade. With industry giants, both public as well as private, pouring billions of dollars into the development of novel radio nucleotide-including treatments, the global valuation is very likely to reach US$ 11,635 million by 2034. The industry-academia collaboration, coupled with robust government policies, hefty healthcare expenditures, increasing awareness, and rising consumer spending on well-being is responsible for the market to grow at an anticipated CAGR of 3.40% through CAGR, especially in developing and developed economies like India, China, the United States, Spain, and the United Kingdom. "The market, which is still in its nascent stages, has great opportunities in the coming future. Companies in the market must collaborate with the government to make the offerings more affordable, feasible, and available," says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) . Key Takeaways from the Market Study The oncology segment dominates the global radiopharmaceutical market with a share of 51.40% in 2024. Based on radioisotope, the technetium-99 leads the radiopharmaceutical market with a share of 47.20% in 2024. The radiopharmaceutical market in India is anticipated to grow at a CAGR of 5.40% through 2034. The radiopharmaceutical market in Malaysia is estimated to rise at a 3.90% CAGR through 2034. The radiopharmaceutical market in Indonesia has the potential to increase at a 3.70% CAGR through 2034. The Thai radiopharmaceutical market is predicted to rise at a 3.20% CAGR through 2034. The radiopharmaceutical market in Spain is very likely to grow at a CAGR of 2.90% through 2034. Competitive Landscape The market for radiopharmaceuticals is still in its early stages with a few companies dominating the international marketplace. The requirement for radiopharmaceuticals is expected to increase significantly due to medical advancements and their wider usage in the medical world, which could provide excellent opportunities for new players to enter the market. Prominent companies in the market include Bayer AG, Bracco Imaging S.p.A., Cardinal Health, Inc., Eli Lilly and Company (Eli Lilly), Curium Pharma, Lantheus Holdings, Inc., Novartis AG, Nordion (Canada) Inc., etc. These companies provide radiopharmaceuticals to healthcare facilities such as hospitals, ambulatory surgical centers, clinics, specialty hospitals, etc. Key components in this market include innovation and keeping up with the latest medical technology. These companies are investing millions of dollars in the development of novel radiopharmaceuticals with improved efficiency. Recent Developments Bayer and PanTera partnered to obtain actinium-225 for radiopharmaceuticals, starting clinical trials in 2024. Ariceum Therapeutics opened a radiopharmaceutical lab in Berlin for R&D on upcoming pipeline candidates in March 2024. Ratio Therapeutics, in March 2024, extended its manufacturing deal with PharmaLogic to expedite production and launch of its FAP-targeted candidate. Purchase now and gain full access to the Radiopharmaceutical Industry report, featuring comprehensive Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives. About the Author: Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher. Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation. Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News. Explore FMI's Extensive Coverage in the Healthcare Domain: Cancer Diagnostics Market by Tumor Biomarkers Tests, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization, and Other Test Types, Forecast, 2023-2033. – Review and Request to Access the Sample Report. Cancer Vaccines Market by Technology, Treatment Method, Application & Region | Forecast 2023 to 2033. - Review and Request to Access the Sample Report. Cancer Biological Therapy market by Product Type, Vehicle Type, Sales Channel & Region | Forecast 2022 to 2032. - Review and Request to Access the Sample Report. Cancer Supportive Care Products Market By Drug Class, Indication, Distribution Channel & Region - Forecast to 2020-2030. - Review and Request to Access the Sample Report. Cancer Tissue Diagnostics Market by Immunohistochemical (IHC) Test and In Situ Hybridization (ISH) Test, Forecast, 2023-2033. - Review and Request to Access the Sample Report. Cancer-Focused Genetic Testing Services Market By Test Type, Cancer Type, Service Provider & Region | Forecast 2022 to 2032. - Review and Request to Access the Sample Report. About Future Market Insights (FMI) Future Market Insights (FMI) is a leading market intelligence and consulting service provider, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, the U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact Us Nandini Singh Sawlani Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, USA T: +1-845-579-5705 For Sales Enquiries: [email protected] Website: LinkedIn | Twitter | Blogs | YouTube Logo: SOURCE Future Market Insights

BERLIN, March 5, 2024 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the opening of its new laboratory facilities on 7 March at its Berlin headquarters to house the research and development of its next generation radiopharmaceutical pipeline candidates and support the transfer of advancing products into the clinic. With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added. It provides Ariceum with the capability to work with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) isotopes for imaging, and beta and alpha isotopes for therapy. The lab is equipped to enable Ariceum to carry out on-site process, method, validation and formulation development as well as preliminary stability analysis of its radiolabeled compounds. Furthermore, the new laboratory will allow Ariceum to conduct non-clinical pharmacology studies for detailed characterization of its first-in-class development candidates. Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: "Following 15 months of construction at our headquarters in Berlin, we are delighted to have opened our brand new, advanced laboratory space. Since our inception in 2021, Ariceum has significantly expanded the team and made important advances in the development of next-generation, targeted radiotherapeutics but we have had to use external radio pharma facilities to enable this. Our new laboratory will give us the internal capability not only to progress the development of our lead radiopharmaceutical candidates but to provide a state-of-the-art research hub to advance R&D collaborations and identify exciting new pipeline candidates. We are very grateful to our team in Berlin who have pushed hard to bring these construction plans to fruition." Notes to Editors About Ariceum Therapeutics Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of 'Marie Curie' whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum's lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), or Merkel Cell Carcinoma, all of which have few treatment options and poor prognosis. Satoreotide is being developed as a 'theranostic' pair for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), which is slated to enter clinical development in 2024. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023. Ariceum Therapeutics, launched in 2021, acquired all rights to Satoreotide from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, United Kingdom and United States of America and with activities currently across the globe. Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For further information, please visit . SOURCE Ariceum Therapeutics